جست‌وجوی استاد و پژوهشگر

Lars Maegdefesselمشاهده پروفایل

استاد

• vascular disease
• atherosclerosis
• aortic aneurysm
• +۴ مورد دیگر

Lars Maegdefessel is a Professor of Molecular Vascular Medicine at the Technical University Munich (TUM), School of Medicine and Health. He leads the Experimental Vascular Medicine unit at Klinikum rechts der Isar and serves as a DZHK Junior Group Leader. His research focuses on the therapeutic and biomarker potential of non-coding RNAs in vascular diseases including atherosclerosis, aortic aneurysm, and related vascular pathologies. Dr. Maegdefessel's research interests center on the role of non-coding RNAs in vascular diseases, with particular focus on the vulnerability of atherosclerotic vascular lesions and the progression and rupture of abdominal aortic aneurysms. His laboratory utilizes unique human biobank materials and various pre-clinical experimental models to investigate novel molecular approaches for combating cardiovascular diseases. His work spans from basic research on microRNAs, long non-coding RNAs, and circular RNAs to translational applications in vascular medicine. Analysis of Dr. Maegdefessel's publication record reveals a strong focus on non-coding RNA mechanisms in vascular pathology, with particular emphasis on atherosclerosis stabilization, aneurysm development, and vascular inflammation. His research has evolved from basic miRNA characterization to sophisticated therapeutic applications including targeted delivery systems and novel biomarker discovery. The publications demonstrate a consistent trajectory toward clinical translation of RNA-based vascular therapeutics. ERC Consolidator Grant (2023) Russel Ross Award from American Heart Association (2023) Heisenberg Professorship of German Research Foundation (2016) Werner Risau Award of American Heart Association (2016) ERC Starting Grant (2015) Prince Daniel Research Award of Swedish Heart and Lung Foundation (2014) Ragnar Söderberg Fellowship in Medicine (2014) Dr. Maegdefessel's research program includes extensive collaboration with international teams and utilizes advanced methodologies including RNA sequencing, microarrays, proteomics, and epigenomic analyses. His laboratory investigates ncRNA function in human vascular tissues and pre-clinical models, with recent work focusing on artery-on-a-chip technology and novel therapeutic delivery systems for vascular applications.

• Stem Cell Differentiation
• Toxicology
• Hepatocyte Biology
• +۲ مورد دیگر

Dr. David Feuerborn is a Researcher at the Leibniz Research Centre for Working Environment and Human Factors (IFADO) in Dortmund, Germany, within the Toxicology department's Regulatory Networks of Stem Cell Differentiation group. His work focuses on modeling stem cell differentiation into hepatocyte-like cells for toxicology applications, with contact details feuerborn@ifado.de and +49 231 1084-344. His research centers on regulatory mechanisms in stem cell differentiation, particularly hepatocyte development influenced by environmental toxins like bisphenols. He employs genome-wide expression profiling and bioinformatic analysis to study transcription factors (HNF4α, FXR) and cellular responses to toxicants, bridging stem cell biology and toxicology. Analysis of his 2018-2022 publications reveals consistent use of iPSC-derived hepatocyte models to assess compound toxicity, with increasing integration of single-cell genomics and computational methods. Key trends include characterizing hybrid cell states, dissecting endocrine disruptor effects, and developing predictive frameworks for transcription factor activity. As part of IFADO's Regulatory Networks of Stem Cell Differentiation team, he collaborates on projects examining molecular pathways governing cell fate decisions in toxicological contexts, contributing to stem cell-based testing methodologies for drug development and safety assessment.

• Immunology
• Type 1 Diabetes Research
• Regenerative Medicine
• +۴ مورد دیگر

Professor Ezio Bonifacio, Ph.D. is a faculty member at Dresden University of Technology affiliated with the Center for Regenerative Therapies Dresden (CRTD). His research spans immunology, regenerative medicine, and metabolic diseases with significant contributions to diabetes research and post-viral syndrome studies. Dr. Bonifacio's primary research interests include immunological profiling in type 1 diabetes, regenerative approaches for pancreatic islet cells, and transcriptomic analysis of Long COVID-19. His work employs cutting-edge single-cell techniques to address fundamental questions in autoimmune diseases and tissue regeneration. As a research leader, he serves as speaker for the Cluster of Excellence 'Center for Regenerative Therapies Dresden (CRTD)' (EXC 168) and previously for the Research Center FZT 111. He currently participates in the International Research Training Group 2251 focused on immunological strategies for metabolic diseases. B/T cell receptor and immune cell profiling in children at high risk for type 1 diabetes Identification and characterization of Long COVID-19 patients using whole blood transcriptomics Optimization of porcine neonatal islets for clinical transplantation therapy Diabetes and regeneration of pancreatic islet cells His research infrastructure includes leadership of the DRESDEN-concept Genome Center, providing advanced genomic capabilities for the research community. Dr. Bonifacio's work bridges fundamental immunological research with clinical applications in regenerative medicine.